Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Results of the Activ8 trial of novel immunotherapy motolimod

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.10.16
Views: 1697

Dr Ezra Cohen - UC San Diego, San Diego, USA

Dr Cohen speaks with ecancertv at ESMO 2016 about the Activ8 trial, which sought to combine cetuximab and chemotherapy with toll-like-receptor agonist motolimod.

He describes the pathways by which motolimod redirects CD8 T cells towards non-immunogenic tumours, though reports the Activ8 trial as a statistically negative trial having not met its end-points.

Thought a negative trial in this instance, he describes the immune activity in a subset of patients who responded best as indicative of motolimods potential for future trials.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation